Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > LATEST
LATEST
-
REGULATORY Deeper CEA Price Cuts Mooted for “Cost Increase” Products: FY2026 Reform Debate
October 16, 2025
-
REGULATORY Vyloy Braced for Price Cut after Cost-Effectiveness Assessment
October 16, 2025
-
REGULATORY Rift Surfaces over What Constitutes “Objective Review” of CEA
September 29, 2025
-
REGULATORY Reblozyl Faces Price Cut after Cost-Effectiveness Assessment
September 11, 2025
-
REGULATORY Industry Urges “Objective Review First” for CEA Reform; Payers Push for Expansion
August 7, 2025
-
REGULATORY Chuikyo Rules Out Long-Term Care Costs in Leqembi CEA, Confirms Price Cut
August 7, 2025
-
REGULATORY Wegovy, Leqvio, Phozevel to Face CEA-Linked Price Cuts in November
August 7, 2025
-
REGULATORY Japan Begins FY2026 CEA Reform Talks, Re-Designation after Market Expansion Up for Debate
July 17, 2025
-
REGULATORY Leqembi Likely to Face 15% Price Cut Under Special CEA Rule
July 10, 2025
-
ORGANIZATION Pharma Labor Platform Calls for Inflation-Responsive Drug Pricing Reforms, Opposes CEA Expansion
July 3, 2025
-
REGULATORY MOF Poised to Discuss Use of CEA System with MHLW: Budget Examiner
June 30, 2025
-
COMMENTARY Honebuto 2025 Approved - The Real Battle for Pharma Lies Ahead
June 23, 2025
-
ORGANIZATION JPMA Ready to Engage with Government on CEA Debates: Statement
June 16, 2025
-
REGULATORY Japan OKs Honebuto Paper with Softened Phrasing on CEA, Sign of Change to Social Security Budgeting
June 16, 2025
-
ORGANIZATION Policy Veterans’ Group Opposes Expansion of CEA Price Adjustments
June 13, 2025
-
REGULATORY Latest Honebuto Draft Erases “Expansion” of CEA after LDP Pushback
June 12, 2025
-
REGULATORY LDP Lawmakers Push Back on Honebuto Draft over CEA, Social Security Budgeting
June 10, 2025
-
REGULATORY Honebuto Draft Urges Promotion of Drug Innovation, but Spells Out CEA Expansion Too
June 9, 2025
-
REGULATORY Early Honebuto Draft Contains CEA Expansion, Ramp-Up of FIH Trial Sites
June 4, 2025
-
REGULATORY MOF Panel Again Presses for Expansion of CEA Scheme: “Spring” Proposal
May 27, 2025
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…